Table 5.
Characteristics of BRAF-mutated patients treated with immunotherapy.
| Patient | BRAF mutation | Regimen | Treatment line | Tumor response | PFS (months) | Status at last follow-up |
|---|---|---|---|---|---|---|
| 1 | V600E | Pembrolizumab | 2 | PR | 8.9 | PR |
| 2 | K601E | Nivolumab + Chemotherapy | 2 | SD | 3.5 | SD |
| 3 | V600E | Nivolumab | 1 | Not measurable | 3.0 | PD |
| 4 | V600E | Nivolumab + Targeted therapy | 3 | SD | 4.1 | PD |
| 5 | V600E | Pembrolizumab + Bevacizumab | 3 | PR | 3.0 | PD |
| 6 | V600E | Nivolumab | 2 | PD | 2.6 | PD |
| 7 | T599dup | Pembrolizumab | 2 | PD | 2.7 | PD |
| 8 | V600E | Pembrolizumab + Targeted therapy | 3 | SD | 5.5 | PD |
| 9 | G466R | Nivolumab + Anlotinib | 2 | PD | 2.0 | PD |
PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival.